140 related articles for article (PubMed ID: 24391119)
21. MDM2 SNP309 modifies the prognostic significance of the p53 mutational status in patients with ovarian cancer.
Hofstetter G; Berger A; Bauer EM; Schuster E; Wolf A; Chamson M; Müller-Holzner E; Reimer D; Braicu EI; Sehouli J; Ulmer H; Cacsire Castillo-Tong D; Zeillinger R; Concin N
Oncol Rep; 2012 Mar; 27(3):673-7. PubMed ID: 22134502
[TBL] [Abstract][Full Text] [Related]
22. MDM2 SNP309 polymorphism is associated with colorectal cancer risk.
Wang W; Du M; Gu D; Zhu L; Chu H; Tong N; Zhang Z; Xu Z; Wang M
Sci Rep; 2014 May; 4():4851. PubMed ID: 24797837
[TBL] [Abstract][Full Text] [Related]
23. MDM2 SNP309 is associated with high grade node positive breast tumours and is in linkage disequilibrium with a novel MDM2 intron 1 polymorphism.
Paulin FE; O'Neill M; McGregor G; Cassidy A; Ashfield A; Ali CW; Munro AJ; Baker L; Purdie CA; Lane DP; Thompson AM
BMC Cancer; 2008 Oct; 8():281. PubMed ID: 18828900
[TBL] [Abstract][Full Text] [Related]
24. Association of the germline TP53 R72P and MDM2 SNP309 variants with breast cancer survival in specific breast tumor subgroups.
van den Broek AJ; Broeks A; Horlings HM; Canisius SV; Braaf LM; Langerød A; Van't Veer LJ; Schmidt MK
Breast Cancer Res Treat; 2011 Nov; 130(2):599-608. PubMed ID: 21667122
[TBL] [Abstract][Full Text] [Related]
25. Influence of MDM2 SNP309 and SNP285 status on the risk of cancer in the breast, prostate, lung and colon.
Gansmo LB; Knappskog S; Romundstad P; Hveem K; Vatten L; Lønning PE
Int J Cancer; 2015 Jul; 137(1):96-103. PubMed ID: 25431177
[TBL] [Abstract][Full Text] [Related]
26. No association between MDM2 SNP309 promoter polymorphism and basal cell carcinoma of the skin.
Wilkening S; Hemminki K; Rudnai P; Gurzau E; Koppova K; Försti A; Kumar R
Br J Dermatol; 2007 Aug; 157(2):375-7. PubMed ID: 17553029
[TBL] [Abstract][Full Text] [Related]
27. No association between SNP309 promoter polymorphism in the MDM2 and cervical cancer in a study from northeastern Brazil.
Meissner Rde V; Barbosa RN; Fernandes JV; Galvão TM; Galvão AF; Oliveira GH
Cancer Detect Prev; 2007; 31(5):371-4. PubMed ID: 18023538
[TBL] [Abstract][Full Text] [Related]
28. Lack of association between the MDM2-SNP309 polymorphism and breast cancer risk.
Petenkaya A; Bozkurt B; Akilli-Ozturk O; Kaya HS; Gur-Dedeoglu B; Yulug IG
Anticancer Res; 2006; 26(6C):4975-7. PubMed ID: 17214373
[TBL] [Abstract][Full Text] [Related]
29. Influence of the MDM2 single nucleotide polymorphism SNP309 on tumour development in BRCA1 mutation carriers.
Copson ER; White HE; Blaydes JP; Robinson DO; Johnson PW; Eccles DM
BMC Cancer; 2006 Mar; 6():80. PubMed ID: 16563154
[TBL] [Abstract][Full Text] [Related]
30. TP53 mutations and MDM2(SNP309) identify subgroups of AML patients with impaired outcome.
Falk IJ; Willander K; Chaireti R; Lund J; Nahi H; Hermanson M; Gréen H; Lotfi K; Söderkvist P
Eur J Haematol; 2015 Apr; 94(4):355-62. PubMed ID: 25156865
[TBL] [Abstract][Full Text] [Related]
31. Prognostic significance of MDM2 gene expression in childhood neuroblastoma.
Inomistova MV; Svergun NM; Khranovska NM; Skachkova OV; Gorbach OI; Klymnyuk GI
Exp Oncol; 2015 Jun; 37(2):111-5. PubMed ID: 26112937
[TBL] [Abstract][Full Text] [Related]
32. MDM2 SNP309 contributes to tumor susceptibility: a meta-analysis.
Wo X; Han D; Sun H; Liu Y; Meng X; Bai J; Chen F; Yu Y; Jin Y; Fu S
J Genet Genomics; 2011 Aug; 38(8):341-50. PubMed ID: 21867960
[TBL] [Abstract][Full Text] [Related]
33. Association between MDM2 SNP309 polymorphism and endometrial cancer risk in Polish women.
Zając A; Stachowiak G; Pertyński T; Romanowicz H; Wilczyński J; Smolarz B
Pol J Pathol; 2012 Dec; 63(4):278-83. PubMed ID: 23359199
[TBL] [Abstract][Full Text] [Related]
34. MDM2 309 polymorphism is associated with missed abortion.
Fang Y; Kong B; Yang Q; Ma D; Qu X
Hum Reprod; 2009 Jun; 24(6):1346-9. PubMed ID: 19246469
[TBL] [Abstract][Full Text] [Related]
35. MDM2 SNP309 associates with accelerated pancreatic adenocarcinoma formation.
Grochola LF; Müller TH; Bond GL; Taubert H; Udelnow A; Würl P
Pancreas; 2010 Jan; 39(1):76-80. PubMed ID: 19752772
[TBL] [Abstract][Full Text] [Related]
36. Impact of the Mdm2(SNP309-G) allele on a murine model of colorectal cancer.
Zhang X; Pageon L; Post SM
Oncogene; 2015 Aug; 34(33):4412-20. PubMed ID: 25435368
[TBL] [Abstract][Full Text] [Related]
37. MDM2 SNP309 accelerates breast and ovarian carcinogenesis in BRCA1 and BRCA2 carriers of Jewish-Ashkenazi descent.
Yarden RI; Friedman E; Metsuyanim S; Olender T; Ben-Asher E; Papa MZ
Breast Cancer Res Treat; 2008 Oct; 111(3):497-504. PubMed ID: 18026875
[TBL] [Abstract][Full Text] [Related]
38. Do CDKN2 p16 540 C>G, CDKN2 p16 580 C>T, and MDM2 SNP309 T>G gene variants act on colorectal cancer development or progression?
Tuna G; Küçükhüseyin O; Arıkan S; Kaytan Sağlam E; Güler E; Cacına C; Oztop O; Turan S; Korkmaz G; Yaylım I
DNA Cell Biol; 2013 Jul; 32(7):400-8. PubMed ID: 23777425
[TBL] [Abstract][Full Text] [Related]
39. Effect of a single nucleotide polymorphism in the murine double minute 2 promoter (SNP309) on the sensitivity to topoisomerase II-targeting drugs.
Nayak MS; Yang JM; Hait WN
Cancer Res; 2007 Jun; 67(12):5831-9. PubMed ID: 17575151
[TBL] [Abstract][Full Text] [Related]
40. Effect of MDM2 SNP309 and p53 codon 72 polymorphisms on lung cancer risk and survival among non-smoking Chinese women in Singapore.
Chua HW; Ng D; Choo S; Lum SS; Li H; Soh LY; Sabapathy K; Seow A
BMC Cancer; 2010 Mar; 10():88. PubMed ID: 20219101
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
